Brief: Mesoblast Says Ryoncil Shows 84% Survival Rate In Children With Sr-Agvhd
26/01/2026 23:48
Jan 26 (Reuters) - Mesoblast Ltd MSB.AX: MESOBLAST LTD - RYONCIL SHOWS 84% SURVIVAL RATE IN CHILDREN WITH SR-AGVHD Source text: ID:nGNX7tzB2c Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M